PSMA ligand targeted compounds and uses thereof
Prostate-specific membrane antigen (PSMA) targeted compounds having formula (I), nanoclusters formed thereof, pharmaceutical compositions comprising a plurality of these compounds, and methods for treating and detecting cancers in a subject are described herein.
1. A composition for detecting and/or treating cancer, the composition comprising a plurality of compounds that include formula (I):
wherein:
n and n 1 are each independently 1, 2, 3, or 4;
L is an optionally substituted aliphatic or heteroaliphatic linking group;
B comprises at least one negatively charged amino acid; and
Z has the formula
wherein Z is directly or indirectly linked to B.
2. The composition of claim 1 , wherein B has the following formula:
wherein m is 1, 2, 3, or 4, X 1 is an amino acid, and wherein Z is directly or indirectly linked to X 1 .
3. The composition of claim 1 , wherein B has the following formula:
wherein m is 1, 2, 3, or 4.
4. The composition of claim 1 , wherein L includes at least one ring selected from the group consisting of an optionally substituted 4 to 7 membered nonaromatic heterocyclic ring and an optionally substituted C4-C7 cycloalkyl ring.
5. The composition of claim 1 , comprising the formula (II):
wherein m, n, and n 1 are each independently 1, 2, 3, or 4, and wherein m 1 is 3-7.
6. The composition of claim 1 , wherein the plurality of compounds has formed gold nanoclusters.
7. The composition of claim 6 , the gold nanoclusters including 10-150 gold atoms.
8. The composition of claim 6 , the gold nanoclusters including 10-40 gold atoms.
9. The composition of claim 6 , wherein the gold nanoclusters are less than about 10 nm in diameter.
10. The composition of claim 6 , wherein the cancer is a PSMA expressing cancer selected from glioma, retinoblastoma, lung cancer, melanoma, breast cancer, ovarian cancer, endometrial cancer, and prostate cancer.
11. The composition of claim 6 , wherein the cancer is prostate cancer.
12. A method for treating prostate cancer comprising:
(a) administering systemically to a subject with prostate cancer a therapeutically effective amount of a composition, the composition comprising a gold nanocluster, the gold nanocluster including a plurality of compounds having formula (I):
wherein n and n 1 are each independently 1, 2, 3, or 4, L is an optionally substituted aliphatic or heteroaliphatic linking group, B comprises at least one negatively charged amino acid, and
Z has the formula
wherein Z is directly or indirectly linked to B; and
(b) irradiating the prostate cancer of the subject, thereby inducing the radiosensitizing effects of the gold nanocluster.
13. The method of claim 12 , further comprising the step of detecting the gold nanocluster selectively targeted to prostate cancer cells of the subject to determine the location and/or distribution of the prostate cancer cells in the subject.
14. The method of claim 13 , wherein the presence of the gold nanocluster is detected in the subject by at least one positron emission tomography (PET) imaging or computer tomography (CT) imaging.
15. The method of claim 12 , wherein the composition is administered by intravenous injection.
16. The method of claim 12 , wherein B has the following formula:
wherein m is 1, 2, 3, or 4, X 1 is an amino acid, and wherein Z is directly or indirectly linked to X 1 .
17. The method of claim 12 , wherein B has the following formula:
wherein m is 1, 2, 3, or 4.
18. The method of claim 12 , wherein L includes at least one ring selected from the group consisting of an optionally substituted 4 to 7 membered nonaromatic heterocyclic ring and an optionally substituted C4-C7 cycloalkyl ring.
19. The method of claim 12 , the compounds comprising the formula (II):
wherein m, n, and n 1 are each independently 1, 2, 3, or 4, and wherein m 1 is 3-7.
20. The method of claim 12 , wherein the gold nanocluster includes about 10 to about 150 gold atoms.
21. The method of claim 12 , wherein the gold nanocluster includes about 10 to about 40 gold atoms.
22. The composition of claim 12 , wherein the gold nanocluster is less than about 10 nm in diameter.
23. The composition of claim 12 , wherein the prostate cancer is irradiated with X-ray radiation.
24. The composition of claim 12 , wherein the prostate cancer is irradiated with gamma ray radiation.